EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A yeast synthetic biotic platform for delivery of therapeutic nanobodies to ameliorate gastrointestinal inflammation

Roger Palou iD, Almer M van der Sloot iD, Aline A Fiebig, Megan T Zangara, Naseer Sangwan, María Sánchez-Osuna, Bushra Ilyas, Haley Zubyk, Michael Cook, Gerard D Wright iD, Brian K Coombes iD, Mike Tyers iD

Disease Models & Mechanisms · 01.02.2026 · 19 (2)

DOI: 10.1242/dmm.052620 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disease Models & Mechanisms, online erschienen am 09.03.2026. Verfasst von Roger Palou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON M5G 0A4, Canada. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Saccharomyces boulardii, Inflammation, Gastrointestinal Tract. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Weston Family Foundation, Genome Canada, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein-based pharmaceuticals, such as engineered antibodies, form a major drug class of steadily increasing market share. However, these biologic medicines are costly to manufacture, are subject to strict supply chain and storage constraints, and often require invasive administration routes. Engineered microbes that secrete bioactive products directly within the microbiome milieu may mitigate these challenges. Here, we describe a cell microfactory platform based on the probiotic yeast Saccharomyces boulardii for the production of nanobody biologics in the gastrointestinal (GI) tract. High-level secretion of nanobodies by S. boulardii was achieved by optimizing promoters, secretion signals and antibody formats. In mice, oral gavage of S. boulardii allowed efficient and transient colonization of the colonic compartment, and in situ production of a therapeutic nanobody directed against tumor necrosis factor (TNF). In a mouse model of chemical-induced colitis, GI-delivery of anti-murine TNF nanobody via live S. boulardii improved both survival and disease severity without causing overt perturbation of microbiome composition. These results position S. boulardii as a synthetic biotic platform for the in situ production and delivery of protein-based therapeutics to the GI tract.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesSaccharomyces boulardiiInflammationGastrointestinal TractDrug Delivery SystemsAnimalsTumor Necrosis Factor-alphaColitisMice, Inbred C57BLDisease Models, Animal

Stichwörter der Autor:innen

Saccharomyces boulardiiInflammatory bowel diseaseSynthetic bioticTNFVHH nanobody

Substanzen

Single-Domain AntibodiesTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON M5G 0A4, Canada.
  • Mila - Québec Artificial Intelligence Institute, Montréal, QC H2S 3H1, Canada.
  • Université de Montréal, Département d'informatique et de recherche opérationnelle, Montréal, QC H3C 3J7, Canada.
  • Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4K1, Canada.
  • Microbial Sequencing and Analytics Resource (MSAAR) Facility, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44106, USA.
  • Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, OH 44106, USA.

ORCID-Profile: Roger Palou, Almer M van der Sloot, Gerard D Wright, Brian K Coombes, Mike Tyers

Förderung

  • Weston Family Foundation
  • Genome Canada
  • CIHR
  • Genome Quebec
  • Canadian Institutes of Health Research

Zitieren

APA

Palou, R., van der Sloot, A. M., Fiebig, A. A., Zangara, M. T., Sangwan, N., Sánchez-Osuna, M., Ilyas, B., Zubyk, H., Cook, M., Wright, G. D., Coombes, B. K., & Tyers, M. (2026). A yeast synthetic biotic platform for delivery of therapeutic nanobodies to ameliorate gastrointestinal inflammation. Disease Models & Mechanisms, 19(2). https://doi.org/10.1242/dmm.052620

Vancouver

Palou R, van der Sloot AM, Fiebig AA, Zangara MT, Sangwan N, Sánchez-Osuna M, et al. A yeast synthetic biotic platform for delivery of therapeutic nanobodies to ameliorate gastrointestinal inflammation. Disease Models & Mechanisms. 2026;19(2). doi:10.1242/dmm.052620

BibTeX
@article{Palou2026,
  author = {Palou, Roger and van der Sloot, Almer M and Fiebig, Aline A and Zangara, Megan T and Sangwan, Naseer and Sánchez-Osuna, María and Ilyas, Bushra and Zubyk, Haley and Cook, Michael and Wright, Gerard D and Coombes, Brian K and Tyers, Mike},
  title = {A yeast synthetic biotic platform for delivery of therapeutic nanobodies to ameliorate gastrointestinal inflammation},
  journal = {Disease Models & Mechanisms},
  year = {2026},
  volume = {19},
  number = {2},
  doi = {10.1242/dmm.052620}
}
Kostenlos starten →